Acadia sells Rare Pediatric Disease Priority Review Voucher for $150M
by
Contributor since / Followers
Contributor since / Followers
13 hours ago
hapabapa
- Acadia Pharmaceuticals (NASDAQ:ACAD) has sold a Rare Pediatric Disease Priority Review Voucher for $150M.
- The company received the voucher in March 2023 after the FDA approved Daybue (trofinetide), a Rett syndrome treatment.
- Acadia said sale proceeds will go to benefit its commercial operations, R&D programs in central nervous system and rare disease, and future business development.